Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

September 12, 2019

Study Completion Date

October 31, 2019

Conditions
GlioblastomaGrade IV AstrocytomaGlioblastoma MultiformeGrade IV Glioma
Interventions
DRUG

MDNA55

MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).

Trial Locations (7)

19107

Hospital of the University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

33486

Boca Raton Regional Hospital, Boca Raton

78229

Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio

90404

John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica

94143

University of California San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Medicenna Therapeutics, Inc.

INDUSTRY

NCT02858895 - Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | Biotech Hunter | Biotech Hunter